Molecular and statistical weaknesses of the p-tau217/Aβ1−42 plasma ratio for alzheimer’s diagnosis
Journal of Molecular Medicine · 2026-12 · 104 (1)
DOI: 10.1007/s00109-026-02676-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 12.05.2026. Verfasst von Christian Griñán Ferré und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Medicinal Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, tau Proteins, Peptide Fragments. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.
Themen: Demenz
Abstract (Originalsprache)
The FDA’s approval of the Lumipulse G p-tau217/Aβ 1−42 plasma ratio enhances access to Alzheimer’s diagnostics but risks confusing convenience with biological accuracy. The assay is scalable and non-invasive, yet it relies on a ratio of two markers that are unstable and only partly specific to the disease, raising concerns about reproducibility and interpretation. The reported performance is solid in carefully selected groups, but is likely to be less robust in broader real-world populations with lower disease prevalence, mixed pathologies, and higher comorbidity. If biomarker-based enrollment is shaped by imperfect specificity, misclassification may propagate into trial recruitment, treatment-effect estimates, and downstream validation. This concern is amplified when biomarkers are validated within partially circular frameworks in which plasma assays, positron emission tomography, cerebrospinal fluid markers, and clinical diagnosis reinforce one another without fully independent neuropathological confirmation. Blood-based assays remain promising, but their clinical use should be guided by rigorous analytical scrutiny, broad validation across diverse populations, standardized pre-analytical handling, and transparent data sharing. The aim of biomarker science should be not striking receiver operating characteristic curves in curated cohorts, but biological fidelity across human heterogeneity and validation grounded in mechanism. Until then, the p-tau217/Aβ 1−42 ratio is best regarded as a useful contextual or research tool rather than a standalone diagnostic benchmark, so that precision medicine does not rest on associations whose causal and mechanistic basis remains insufficiently established. Its most appropriate use may be in longitudinal monitoring within the same individual, where changes over time may be more informative than a single threshold-based diagnostic result.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Medicinal Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
- Institut de Neurociències de la Universitat de Barcelona, Barcelona, Spain.
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Pharmacology and Medicinal Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain. pallas@ub.edu.
- Institut de Neurociències de la Universitat de Barcelona, Barcelona, Spain. pallas@ub.edu.
- Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. pallas@ub.edu.
Förderung
- Universitat de Barcelona
Zitieren
APA
Ferré, C. G., Pallàs, M., & Franco, R. (2026). Molecular and statistical weaknesses of the p-tau217/Aβ1−42 plasma ratio for alzheimer’s diagnosis. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02676-8
Vancouver
Ferré CG, Pallàs M, Franco R. Molecular and statistical weaknesses of the p-tau217/Aβ1−42 plasma ratio for alzheimer’s diagnosis. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02676-8
BibTeX
@article{Ferr2026,
author = {Ferré, Christian Griñán and Pallàs, Mercè and Franco, Rafael},
title = {Molecular and statistical weaknesses of the p-tau217/Aβ1−42 plasma ratio for alzheimer’s diagnosis},
journal = {Journal of Molecular Medicine},
year = {2026},
volume = {104},
number = {1},
doi = {10.1007/s00109-026-02676-8}
}
EUVIMED